Gal Dubnov-Raz.

Amir Tirosh, M.D ., Ph.D., Iris Shai, R.D., Ph.D., Arnon Afek, M.D., M.H.A., Gal Dubnov-Raz, M.D., Nir Ayalon, M.D., Barak Gordon, M.D., Estela Derazne, M.Sc., Dorit Tzur, M.B.A., Ari Shamis, M.D., M.P.A., Shlomo Vinker, M.D., and Assaf Rudich, M.D., Ph.D.: Adolescent BMI Risk and Trajectory of Diabetes versus Coronary Disease Although obesity in adulthood is a well-documented risk factor for both type 2 diabetes and cardiovascular system disease, it remains unclear whether an extended history of relative overweight, starting previous in life, poses an additional risk.

Results Patients and Treatment There were no substantial imbalances in the demographic or ocular characteristics of the analysis groups at baseline . Fulfillment of eligibility requirements was confirmed by central review of images for 1143 of 1185 patients . All but 3 patients had evidence of choroidal neovascularization on OCT or fluorescein angiography and continuing with the designated treatment. Among the 1161 individuals who were alive 12 months after enrollment, visual-acuity scores were available for 1105 , with proportions which range from 93.8 percent to 97.3 percent among the four study organizations. After completion of the overview of OCT scans by the reading center, treatment decisions by study ophthalmologists were in keeping with the retreatment process for 2336 of 3268 examinations in the group assigned to ranibizumab as needed and for 2328 of 3133 examinations in the group assigned to bevacizumab since needed.